3.22
-0.62%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Australian Clinical Labs
Its shares trade on ASX under the ticker ACL.AX. It has been listed since 14 May 2021. In the fiscal year to 30 June 2026, it reported revenue of A$729.5m and net income of A$23.7m. At that date it held total assets of A$592.7m and shareholders' equity of A$149.5m.
Australian Clinical Labs Ltd. engages in the provision of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. The company performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. The company has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 14 May 2021
- Employees
- 5,115
- Website
- clinicallabs.com.au ↗
Leadership
Pay as last reported
- Mr. Stephen RocheIndependent Non-Executive Chairman of the BoardA$3,260
- Ms. Melinda McgrathChief Executive Officer, Executive Director, since 2020A$3.9m
- Mr. Matthew CordingleyChief Financial OfficerA$757,595
- Ms. Eleanor PadmanCompany Secretary
- Ms. Sarah ButlerNon-Executive DirectorA$52,978
- Mr. Grant JefferyNon-Executive DirectorA$52,978
- Ms. Christine BartlettNon-Executive Independent DirectorA$144,590
- Mr. Mark HaberlinNon-Executive Independent DirectorA$146,318
- Dr. Leanne RoweNon-Executive Independent DirectorA$131,182
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 44
- Social
- 77
- Governance
- 22
- Direct emissions (scope 1)
- 3,042 t
- Energy emissions (scope 2)
- 8,658 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Australian Clinical Labs Ltd operates in multiple Australian states including Victoria and Queensland.
- The company provides a wide range of pathology services such as molecular genetics and cardiac testing.
- With 5115 employees, it has a strong workforce for delivering comprehensive pathology solutions.
Weaknesses
- The company's services are limited to Australia with no international expansion mentioned.
- Operations are concentrated in specific Australian regions without broader geographic diversification.
- No mention of digital transformation initiatives within the pathology service offerings.
Opportunities
- Expanding into international markets could leverage Australia's reputation in health care.
- Growing demand for genetic carrier screening and molecular testing presents new revenue streams.
- Collaborating with hospitals for specialized services like obstetrics and gynecology could increase market share.
Threats
- Rising healthcare costs may reduce client spending on non-essential pathology tests.
- Regulatory changes in Australia could impact service delivery and compliance.
- Economic downturns might affect corporate clients' budgets for drug and alcohol testing services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.